Hetao Shenzhen–Hong Kong Science & Technology Innovation Cooperation Zone
河套深港科技创新合作区
A small cross-border innovation zone straddling the Shenzhen–Hong Kong boundary in Futian, purpose-built to let researchers, capital and materials move between the two systems — including a dedicated biopharma cluster.
- Location
- Futian District (Hetao) · Shenzhen
- Visit window
- From the Nanshan base · Jul 13–31
- Source status
- high confidenceprofiled
Next action
Prepare the private outreach route and meeting ask; keep contact details out of the app.
Why now: Visit window · From the Nanshan base · Jul 13–31
What they do
The Hetao SZ–HK S&T Innovation Cooperation Zone (~3.89 km², a Shenzhen Park plus a Hong Kong Park at the Lok Ma Chau Loop) is a cross-border innovation zone in southern Futian bordering Hong Kong. Its International Biomedicine Industrial Park hosts AI-bio and biopharma tenants and institutes, an on-site NMPA GBA drug-review sub-centre and clinical-trial centre, mid-test (pilot) platforms, and a special regime for centralised customs clearance, cross-border biological-sample and clinical-data flow, and dual-currency funds.
Why it matters
The cross-border sourcing and dual-market base story: easier movement of strains, samples, reagents and equipment across the SZ–HK boundary, shared mid-test/pilot-fermentation labs, and an AI-bio peer ecosystem — a potential GBA landing point and HK-facing bridge for Pure Advance's discovery + biomanufacturing platform. The cluster skews human drug discovery, devices and cell & gene with no verified microbial/agri-microbe tenant, which is likely Pure Advance's wedge; an agricultural biocontrol also sits under a different regulatory/partner map than a human drug.
Visit objective & route
Scope landing support for a foreign biotech, the cross-border customs/sample-transfer regime, mid-test/pilot-fermentation platform access, and which tenants touch microbial/fermentation work; identify where a future GBA presence or supplier base could sit.
Approach route
On the cohort itinerary (28 Jul 2026); warm-intro route via KAUST's Shenzhen hub and CUHK-SZ MoU plus the zone's investment-promotion / e-Station landing desk. Confirm whether the stop is the exhibition centre or a working biopharma-park site.
Talking points
- For a foreign (Saudi) biotech with no China entity, what is the real landing path into the biomedicine park / mid-test cluster — and can we host a wet-lab + pilot-scale fermentation bench rather than build?
- How does centralised customs clearance for research materials work for importing microbial strains, reagents and fermentation consumables — timelines, restricted lists, sponsor?
- Which named tenants or institutes touch microbial / synthetic-biology / agricultural-microbe / fermentation work that we could partner or co-locate with?
- Bring the Pure Advance one-pager, a cross-border sourcing / sample-flow needs brief, and an NDA template.
Open questions
- Current channel for company landing / investment promotion (none confirmed).
- Specific Life & Green Valley tenants/anchors relevant to microbial discovery / biomanufacturing / agri-bio, and secondarily topical-care.
- Practical eligibility and process for a foreign (Saudi) biotech to engage or co-locate, and HK-park access logistics.
Risks & unknowns
- No verified microbial / synthetic-biology / agri-microbe tenant — cluster skews human drug discovery, devices and cell & gene; tenant fit still depends on introductions.
- The product is an agricultural biocontrol, not a human drug — the regulatory and partner map differs from the biopharma tenants here.
- Confirm whether the stop is the exhibition centre or a working biopharma-park site before setting expectations.
Private-pack boundary